Tìm theo
Cerivastatin
hypolipidemic agents
Thuốc Gốc
Small Molecule
CAS: 145599-86-6
ATC: C10AA06
ĐG : Bayer Healthcare , http://www.bayerhealthcare.com
CTHH: C26H34FNO5
PTK: 459.5503
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C26H34FNO5
Phân tử khối
459.5503
Monoisotopic mass
459.242101408
InChI
InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
InChI Key
InChIKey=SEERZIQQUAZTOL-ANMDKAQQSA-N
IUPAC Name
(3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
Traditional IUPAC Name
cerivastatin
SMILES
COCC1=C(C2=CC=C(F)C=C2)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C(C(C)C)N=C1C(C)C
Độ hòa tan
Highly solubility
logP
3.4
logS
-5
pKa (strongest acidic)
4.05
pKa (Strongest Basic)
5.58
PSA
99.88 Å2
Refractivity
126.82 m3·mol-1
Polarizability
50.23 Å3
Rotatable Bond Count
11
H Bond Acceptor Count
6
H Bond Donor Count
3
Physiological Charge
-1
Number of Rings
2
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Cerivastatin, a competitive HMG-CoA reductase inhibitor effective in lowering LDL cholesterol and triglycerides, is used to treat primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb).
Cơ Chế Tác Dụng : On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market. Cerivastatin competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for converting HMG-CoA to mevalonate. As mevalonate is a precursor of sterols such as cholesterol, this results in a decrease in cholesterol in hepatic cells, upregulation of LDL-receptors, and an increase in hepatic uptake of LDL-cholesterol from the circulation.
Dược Động Học :
▧ Absorption :
The mean absolute oral bioavailability 60% (range 39 - 101%).
▧ Protein binding :
More than 99% of the circulating drug is bound to plasma proteins (80% to albumin).
▧ Metabolism :
Hepatic. Biotransformation pathways for cerivastatin in humans include the following: demethylation of the benzylic methyl ether to form Ml and hydroxylation of the methyl group in the 6'-isopropyl moiety to form M23.
▧ Half Life :
2-3 hours
Độc Tính : Rhabdomyolysis, liver concerns
Chỉ Định : Used as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.
Tương Tác Thuốc :
  • Bezafibrate Increased risk of myopathy/rhabdomyolysis
  • Bosentan Bosentan may decrease the serum concentration of cerivastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if bosentan is initiated, discontinued or dose changed.
  • Clarithromycin The macrolide, clarithromycin, may increase the toxicity of the statin, cerivastatin.
  • Colchicine Increased risk of rhabdomyolysis with this combination
  • Cyclosporine Possible myopathy and rhabdomyolysis
  • Diltiazem Diltiazem may increase the serum concentration of cerivastatin. Cerivastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.
  • Erythromycin The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin.
  • Fenofibrate Increased risk of myopathy/rhabdomyolysis
  • Gemfibrozil Increased risk of myopathy/rhabdomyolysis
  • Imatinib Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if imatinib is initiated, discontinued or dose changed.
  • Itraconazole Increased risk of myopathy/rhabdomyolysis
  • Josamycin The macrolide, josamycin, may increase the toxicity of the statin, cerivastatin.
  • Ketoconazole Increased risk of myopathy/rhabdomyolysis
  • Nefazodone Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if nefazodone is initiated, discontinued or dose changed.
  • Quinupristin This combination presents an increased risk of toxicity
  • Rifabutin Rifabutin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifabutin is initiated, discontinued or dose changed.
  • Rifampicin Rifampin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifampin is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Tablet - Oral
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Baycol
  • Công ty :
    Sản phẩm biệt dược : Lipobay
  • Công ty :
    Sản phẩm biệt dược : Rivastatin
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00439
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=446156
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505877
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07966
ChemSpider
http://www.chemspider.com/Chemical-Structure.393588.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=18376
PharmGKB
http://www.pharmgkb.org/drug/PA448897
Wikipedia
http://en.wikipedia.org/wiki/Cerivastatin
RxList
http://www.rxlist.com/cgi/generic/cerivastat.htm
Drugs.com
http://www.drugs.com/mtm/cerivastatin.html
... loading
... loading